Wilmington Savings Fund Society FSB Acquires 343 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Wilmington Savings Fund Society FSB boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,676 shares of the company’s stock after acquiring an additional 343 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Neurocrine Biosciences were worth $502,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Golden State Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $25,000. Brooklyn Investment Group boosted its stake in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares in the last quarter. R Squared Ltd acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at $61,000. Finally, UMB Bank n.a. boosted its stake in Neurocrine Biosciences by 211.6% in the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after buying an additional 309 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling

In other news, insider Ingrid Delaet sold 272 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 222,693 shares of company stock valued at $32,718,279. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on NBIX shares. Barclays upped their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Royal Bank of Canada dropped their price objective on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a report on Tuesday. They set a “hold” rating and a $138.00 price objective for the company. Wedbush dropped their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, BMO Capital Markets cut their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Trading Down 1.6 %

Neurocrine Biosciences stock opened at $116.85 on Wednesday. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm has a market capitalization of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33. The business has a 50-day moving average of $138.66 and a 200-day moving average of $131.23.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.